Use of generic drugs on the rise, data show

Share this article:
Almost two-thirds of prescriptions filled for Medicare beneficiaries are for generic, rather than brand-name, drugs, according to government data. That proportion is higher than in the under-65 age group and helps lower the projected costs of the Medicare drug benefit. The Centers for Medicare and Medicaid Services, which runs the federal program for the elderly and disabled, found that 61% of seniors’ prescriptions were for generic medications in the third quarter, the third consecutive quarter of growth in generic drug use. The National Association of Chain Drug Stores was also expected to announce that use of generic drugs rose to almost 53% of privately insured Americans, from 48% in 2005. Increased use of generics has been given as one reason why the growth in US health care spending has slowed in recent years. Generic alternatives have also allowed seniors to delay reaching the Medicare benefit’s coverage gap, also known as the “doughnut hole,” or avoid it altogether. The agency encourages the use of generic drugs, according to The Wall Street Journal report.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...